Image 1 of 1
Image 1 of 1
Image 1 of 1
Image 1 of 1
This listing combines 20 mg retatrutide with 40 mg tirzepatide, for 60 mg total. Retatrutide targets GLP-1, GIP, and glucagon receptors, while tirzepatide targets GLP-1 and GIP receptors. It brings overlapping incretin mechanisms into one research blend.
Key research interests
• Overlapping incretin receptor activity
• Combined metabolic signaling
• Blend compatibility and characterization
Not for human or veterinary use
This listing combines 20 mg retatrutide with 40 mg tirzepatide, for 60 mg total. Retatrutide targets GLP-1, GIP, and glucagon receptors, while tirzepatide targets GLP-1 and GIP receptors. It brings overlapping incretin mechanisms into one research blend.
Key research interests
• Overlapping incretin receptor activity
• Combined metabolic signaling
• Blend compatibility and characterization
Not for human or veterinary use